Abiopharma

ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)

Quantum Corporation Files Form 12b-25 Notification of Late Filing

Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Improved Growth Measures in Pediatric Patients with Classic Congenital Adrenal Hyperplasia at ENDO 2026

BlockchAIn Announces Corporate Name Change to AIB Data Centers Inc.

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

Alto Ingredients, Inc. Completes Transaction to Monetize All 2025 45Z Clean Fuel Production Tax Credits

Integra LifeSciences to Present at the 2026 Truist Securities MedTech Conference

CELSIUS HOLDINGS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Celsius Holdings, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CELH

RBB Bancorp Announces Authorized Common Stock Repurchase Plan and Partial Redemption of Subordinated Debt

Fate Therapeutics Appoints Laura Hamill to Board of Directors